RephImmune Joins Tech4Eva 2025 as the Only Taiwan Startup Selected: Recognized for Our Breakthrough T Cell Therapy Targeting Women’s Cancers
RephImmune Biotechnology Inc. is honored to announce our selection into Tech4Eva 2025, Switzerland’s premier global accelerator program focused on innovation in women’s health. Among 195 applicants from 42 countries, RephImmune is proud to be the only startup from Taiwan chosen for this year’s cohort.
Now in its fifth year, Tech4Eva is co-founded by Groupe Mutuel and EPFL Innovation Park and aims to foster cutting-edge solutions in reproductive health, menopause, oncology, maternal care, and healthy aging. This year’s record-breaking number of applicants reflects the growing global demand and investment in femtech, a market projected to exceed $60 billion USD in 2025 and double in the next eight years.
Lan Zuo Gillet, Director of Tech4Eva, stated: “This year, we selected more science-driven femtech startups focused on women-specific cancers and other medical challenges. We believe in bridging the gap between scientific innovation and market implementation.”
RephImmune’s selection recognizes the innovation behind our lead product, RACE-T, a next-generation engineered T cell therapy designed to target ovarian cancer and other solid tumors. RACE-T is engineered to be safer, more durable, and more effective: offering new hope for women battling difficult-to-treat cancers.
Joining Tech4Eva allows RephImmune to connect with leading healthcare institutions, investors, and experts worldwide. We are committed to accelerating the global impact of our science and representing Taiwan’s biotech innovation on the international stage.
